Research programme: beta amyloid aggregation inhibitors - Astellas Pharma/Pfizer

Drug Profile

Research programme: beta amyloid aggregation inhibitors - Astellas Pharma/Pfizer

Alternative Names: PD 0118057; PD 0202091

Latest Information Update: 03 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astellas Pharma; Pfizer
  • Class Anthranilic acids; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 03 Aug 2009 Preclinical development is ongoing in USA and Japan
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 10 Sep 2004 Preclinical trials in Alzheimer's disease in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top